Request Free Sample ×
Preimplantation Genetic Testing Market Research Report - Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Preimplantation Genetic Testing Market

ID: MRFR/HC/6649-HCR
200 Pages
Nidhi Mandole, Rahul Gotadki
Last Updated: May 22, 2026
Preimplantation Genetic Testing Market Research Report: Size, Share, Trend Analysis By Applications (Diagnostic Testing, Carrier Screening, Embryo Selection), By Technique (Polymerase Chain Reaction, Next Generation Sequencing, Fluorescence In Situ Hybridization, Single Nucleotide Polymorphism), By End Use (Fertility Clinics, Research Laboratories, Hospitals), By Client Type (Individuals, Healthcare Providers, Healthcare Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Preimplantation Genetic Testing Market Infographic
Summary Table of Contents Segmentation Methodology Download PDF

Preimplantation Genetic Testing Market Summary

The Preimplantation Genetic Testing Market size was valued at USD 2.11 Billion in 2024. The market is projected to grow from USD 2.26 Billion in 2025 to USD 4.492 Billion by 2035, exhibiting a CAGR of 7.11% during the forecast period 2025-2035. North America led the market with over 42.65% share, generating around USD 0.9 billion in revenue.
 
The global market is expanding due to rising infertility rates, increasing awareness of genetic disorders, and growing adoption of assisted reproductive technologies. Key trends include advancements in next-generation sequencing, integration of AI in genetic analysis, and increasing demand for personalized reproductive solutions to improve pregnancy success rates and prevent hereditary diseases globally.
 
According to WHO, approximately 1 in 6 people globally (about 17.5%) experience infertility, highlighting strong demand for assisted reproductive technologies including IVF and genetic testing. CDC reports over 238,000 ART cycles in the U.S. (2022), reflecting increasing clinical reliance on embryo screening and reproductive genetic solutions.

Key Market Trends & Highlights

The Preimplantation Genetic Testing Market is experiencing robust growth driven by technological advancements and increasing public awareness.

  • North America holds 42.65% global share in 2024, supported by advanced fertility clinics and genetic screening infrastructure.
  • Europe valued at USD 0.63 Billion in 2024, capturing nearly 30% market share with strong regulatory support.
  • Global infertility affects 1 in 6 people (WHO), accelerating demand for assisted reproductive and genetic testing solutions.
  • ART cycles exceed 238,000 annually in the U.S. (CDC), significantly boosting embryo screening and testing demand.

Market Size & Forecast

2024 Market Size 2.11 (USD Billion)
2035 Market Size 4.492 (USD Billion)
CAGR (2025 - 2035) 7.11%

Major Players

Companies such as Illumina (US), Thermo Fisher Scientific (US), Fulgent Genetics (US), Natera (US), CooperSurgical (US), Preimplantation Genetic Diagnosis (UK), Genea (AU), Reproductive Health Technologies (US), Mayo Clinic (US) are some of the major participants in the global market.

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Preimplantation Genetic Testing Market Trends

The Preimplantation Genetic Testing Market is currently experiencing notable growth, driven by advancements in genetic technologies and increasing awareness regarding genetic disorders. As more individuals and couples seek to understand their genetic makeup, the demand for preimplantation genetic testing has surged. This testing allows for the identification of genetic abnormalities in embryos before implantation, thereby enhancing the chances of successful pregnancies and healthy offspring.

Furthermore, the rising prevalence of hereditary diseases and the growing acceptance of assisted reproductive technologies contribute to the market's expansion. In addition, the global market is influenced by evolving regulatory frameworks and ethical considerations surrounding genetic testing. As healthcare providers and patients navigate these complexities, the global market is likely to adapt, fostering innovation and improving accessibility.

The integration of artificial intelligence and machine learning into genetic testing processes may also enhance accuracy and efficiency, potentially reshaping the landscape of reproductive health. Overall, the global market appears poised for continued evolution, reflecting broader trends in healthcare and genetics.

Technological Advancements

The global industry trends is witnessing rapid technological advancements that enhance testing accuracy and efficiency. Innovations in sequencing technologies and bioinformatics tools are streamlining the analysis of genetic material, allowing for more precise identification of genetic disorders. This trend not only improves patient outcomes but also encourages wider adoption of testing services.

  • CDC ART reports show continuous improvement in IVF success rates, with advanced techniques like genetic screening contributing to over 90,000 live births annually in the U.S. via ART cycles. Adoption of NGS and bioinformatics is enhancing embryo selection accuracy, reducing implantation failure rates significantly.

Increased Awareness and Acceptance

There is a growing awareness and acceptance of preimplantation genetic testing among prospective parents. As educational initiatives and media coverage highlight the benefits of genetic testing, more individuals are considering these options during their family planning. This trend is likely to drive demand for testing services, as couples seek to mitigate the risks of genetic disorders.

  • UNICEF highlights that reproductive health awareness programs now reach 100+ countries, improving early screening adoption and maternal health literacy. This has significantly increased acceptance of genetic testing in reproductive planning, supporting higher uptake of preimplantation genetic diagnostics in fertility clinics globally.

Regulatory Developments

The regulatory landscape surrounding genetic testing is evolving, impacting the global market. As governments and health organizations establish guidelines and standards for genetic testing, the market may experience shifts in compliance requirements. These developments could influence the availability and accessibility of testing services, shaping the future of reproductive health.

  • ECDC and WHO collaborative reproductive health frameworks emphasize standardized genetic testing protocols across regions, improving safety and compliance. Over 60+ countries have updated assisted reproduction guidelines, ensuring ethical use of embryo screening technologies and expanding regulated access to genetic testing services.

Preimplantation Genetic Testing Market Drivers

Rising Infertility Rates

The increasing prevalence of infertility is a notable driver for the Preimplantation Genetic Testing Industry. Factors such as delayed childbearing, lifestyle changes, and environmental influences contribute to this trend. According to recent statistics, infertility affects approximately 10-15% of couples worldwide, leading to a heightened demand for assisted reproductive technologies.
 
Preimplantation genetic testing offers a solution by enabling the selection of genetically healthy embryos, thereby improving the chances of successful pregnancies. As more individuals and couples seek fertility treatments, the global market for preimplantation genetic testing is likely to expand, reflecting the urgent need for effective reproductive solutions.

Technological Innovations

Technological advancements in genetic testing methodologies are propelling the Preimplantation Genetic Testing Industry forward. Innovations such as next-generation sequencing (NGS) and improved bioinformatics tools enhance the accuracy and efficiency of genetic testing. These technologies allow for comprehensive analysis of embryos, identifying genetic abnormalities with greater precision.
 
The global market has witnessed a surge in the adoption of these advanced techniques, which not only improve diagnostic capabilities but also reduce the time required for testing. As the technology continues to evolve, it is expected that the market will experience significant growth, driven by the demand for more reliable and faster testing solutions.

Increased Public Awareness

Growing public awareness regarding genetic disorders and the benefits of preimplantation genetic testing is a crucial driver for the Preimplantation Genetic Testing Industry. Educational campaigns and media coverage have played a pivotal role in informing potential parents about the advantages of genetic testing in preventing hereditary diseases.
 
As individuals become more knowledgeable about the implications of genetic conditions, the demand for preimplantation genetic testing is likely to rise. This heightened awareness not only encourages couples to consider genetic testing as part of their reproductive planning but also fosters a more informed dialogue about reproductive health, thereby expanding the market.

Regulatory Support and Guidelines

The establishment of supportive regulatory frameworks is influencing the Preimplantation Genetic Testing Industry positively. Governments and health organizations are increasingly recognizing the importance of genetic testing in reproductive health. Guidelines that promote the safe and ethical use of preimplantation genetic testing are being developed, which may enhance public trust and acceptance.
 
Furthermore, regulatory approvals for new testing technologies can facilitate market entry for innovative solutions. As these frameworks evolve, they are likely to create a more conducive environment for the growth of the market, encouraging investment and research in this field.

Rising Demand for Personalized Medicine

The shift towards personalized medicine is significantly impacting the Preimplantation Genetic Testing Industry. As healthcare moves towards tailored treatment plans based on individual genetic profiles, preimplantation genetic testing aligns perfectly with this trend. Couples are increasingly seeking personalized approaches to family planning, which includes selecting embryos based on genetic compatibility and health.
 
This demand for customized reproductive solutions is expected to drive market growth, as preimplantation genetic testing provides essential information that aids in making informed decisions. The integration of personalized medicine principles into reproductive health is likely to enhance the appeal and adoption of preimplantation genetic testing.

Market Segment Insights

By Application: Diagnostic Testing (Largest) vs. Carrier Screening (Fastest-Growing)

The global Preimplantation Genetic Testing Market is primarily composed of three key application segments: Diagnostic Testing, Carrier Screening, and Embryo Selection. Diagnostic Testing holds the largest market share at 52% due to its critical role in identifying genetic abnormalities before embryo implantation. Carrier Screening, on the other hand, is rapidly gaining traction as more prospective parents seek to understand their genetic risks, thereby driving significant growth in this segment. Embryo Selection remains crucial but has a comparatively smaller share in the overall market dynamics.

Testing Applications: Diagnostic Testing (Dominant) vs. Carrier Screening (Emerging)

In the market, Diagnostic Testing is the dominant application, providing essential insights into genetic conditions of embryos, therefore guiding implantation decisions. This segment benefits from advanced technologies that enhance accuracy and reliability, solidifying its essential role in reproductive health. Conversely, Carrier Screening is emerging as a vital part of family planning, allowing parents to assess the risk of passing on genetic disorders. As awareness increases and genetic testing technologies evolve, the demand for Carrier Screening is surging, making it a significant player in the market and appealing to a younger demographic interested in proactive genetics.

By Technique: Polymerase Chain Reaction (Largest) vs. Next Generation Sequencing (Fastest-Growing)

In the Preimplantation Genetic Testing Market, the Polymerase Chain Reaction (PCR) technique holds a significant market share of 58% due to its long-standing application in genetic testing. PCR's ability to amplify DNA with high precision has made it the go-to method for many laboratories. Following closely is Next Generation Sequencing (NGS), which, while currently smaller in market share than PCR, is rapidly gaining traction due to its simultaneous multi-gene analysis capabilities, offering more comprehensive testing options to clinicians.

PCR (Dominant) vs. NGS (Emerging)

Polymerase Chain Reaction (PCR) is recognized as the dominant technique in the market owing to its reliability and established protocols in amplifying specific DNA sequences. It is widely utilized for target identification, mutation detection, and genotyping. In contrast, Next Generation Sequencing (NGS) is emerging as a revolutionary force, appealing to those seeking extensive genetic insights. Its ability to conduct large-scale sequencing projects efficiently positions it favorably in a market that values innovation, making it a crucial player as healthcare providers increasingly adopt technology-driven solutions.

By End Use: Fertility Clinics (Largest) vs. Research Laboratories (Fastest-Growing)

In the Preimplantation Genetic Testing Market, the distribution of market share among end-use segments illustrates a notable trend where fertility clinics hold the largest share at 61%. This segment thrives due to the rising number of couples seeking assisted reproductive technologies, as well as advancements in genetic testing methods. Meanwhile, Research Laboratories are emerging as a significant player in this market, capitalizing on increased funding for genetic research and innovation that caters to evolving healthcare needs. The growth trends in this segment are primarily driven by technological advancements and increasing awareness regarding genetic disorders. Fertility Clinics continue to expand their services to accommodate a growing patient base, while Research Laboratories are quickly adapting to the demand for robust genetic testing procedures, establishing their essential role in enhancing patient outcomes and advancing the field of reproductive health.

Fertility Clinics: Dominant vs. Research Laboratories: Emerging

Fertility Clinics are pivotal in the market share, characterized by their integration of advanced genetic testing techniques into in vitro fertilization (IVF) protocols. As the dominant player, they not only offer services to ensure successful pregnancies but also enhance the understanding of genetic diseases, thus attracting a steady influx of patients. On the other hand, Research Laboratories represent an emerging force with their focus on innovative genetic testing methods and collaboration with healthcare providers. These labs are essential for developing new genetic testing solutions, thus contributing to a faster turnaround in research and applications. Their role is becoming increasingly significant as they pave the way for advancements that influence fertility treatments and genetic counseling.

By Client Type: Individuals (Largest) vs. Healthcare Providers (Fastest-Growing)

The Preimplantation Genetic Testing Market is characterized by a diverse client base, including Individuals, Healthcare Providers, and Healthcare Institutions. Among these, individuals constitute the largest segment at 54%, driven by the increasing adoption of genetic testing for reproductive health. Healthcare Providers, while smaller in overall market share, are rapidly gaining ground as they embrace genetic testing to enhance patient care and outcomes. This trend highlights the critical role of personalized medicine and the need for tailored solutions in reproductive healthcare.

Healthcare Providers (Dominant) vs. Healthcare Institutions (Emerging)

While Healthcare Providers play a dominant role in the market share, Healthcare Institutions are emerging as significant players. Healthcare Providers leverage their direct relationships with patients, ensuring a more personalized approach to genetic testing services. They implement advanced technologies and stay updated with the latest genetic research to provide optimal solutions for individuals seeking clarity in reproductive options. Conversely, Healthcare Institutions are increasingly recognizing the importance of genetic testing, contributing to the market's growth by integrating these services within broader healthcare offerings. This integration allows institutions to offer comprehensive reproductive care, making them an essential stakeholder in the evolving landscape of genetic testing.

Get more detailed insights about Preimplantation Genetic Testing Market
Request Free Sample

Regional Insights

The Preimplantation Genetic Testing Market share is experiencing substantial growth, with North America being a major contributor, valued at 0.8 USD Billion in 2024 and projected to reach 1.75 USD Billion by 2035. This region dominates largely due to advanced healthcare infrastructure and high acceptance of genetic testing technologies.

  • CDC reports over 238,000 assisted reproductive technology cycles annually in the U.S., with continuous growth in embryo genetic screening adoption. High healthcare spending and advanced fertility clinic networks support widespread use of preimplantation genetic testing, improving pregnancy success rates and reducing genetic disorder risks.

Europe follows closely, valued at 0.6 USD Billion in 2024 and expected to grow to 1.25 USD Billion, as it benefits from strong regulatory support and rising awareness about genetic disorders.

  • ECDC and WHO reproductive health initiatives support standardized genetic screening policies across Europe. With rising infertility awareness and structured healthcare systems, Europe accounts for a significant share of ART adoption, supported by increasing accessibility of regulated fertility treatments and genetic diagnostic services.

In the APAC region, the market is valued at 0.55 USD Billion this year, with future estimates of 1.2 USD Billion, driven by increasing medical tourism and healthcare expenditure.South America, while smaller with valuations of 0.1 USD Billion in 2024 and 0.25 USD Billion in 2035, shows potential growth as awareness about genetic testing rises. Conversely, the Middle East and Africa (MEA) segment remains the least valued at 0.06 USD Billion in 2024, projected to decline slightly, indicating challenges in healthcare accessibility.

The overall growth in these regions reflects increasing demand for advanced reproductive technologies, shaping the Global market landscape significantly.

Preimplantation Genetic Testing Market Regional Image

Key Players and Competitive Insights

The Global Preimplantation Genetic Testing Market is characterized by a rapidly evolving landscape driven by technological advancements and increasing demand for genetic testing in assisted reproductive technologies. The competitive environment is shaped by key players who are consistently innovating and expanding their product offerings to cater to a diverse range of applications within reproductive medicine.
 
Market dynamics are influenced by factors such as regulatory changes, partnerships, mergers, and acquisitions that facilitate growth and enhance service delivery.  As awareness regarding genetic disorders and the importance of early diagnosis continues to rise among prospective parents, companies in this sector are focusing on delivering comprehensive solutions that not only ensure improved success rates in in vitro fertilization procedures but also contribute to the overall well-being of future generations. BioMarin Pharmaceutical stands out within the Global market with a robust focus on developing solutions aimed at addressing genetic conditions.
 
The company's strength lies in its commitment to research and development, which enables it to leverage cutting-edge technologies in genetic testing. BioMarin Pharmaceutical distinguishes itself with a strong portfolio of genetic therapies and diagnostic tools that facilitate preimplantation genetic analysis. The firm has established a notable presence in the market, supported by its extensive network of collaborations and partnerships that enhance its outreach and capability to deliver specialized genetic testing services.
 
This strategic positioning allows BioMarin Pharmaceutical to adapt quickly to market needs and consumer demands, solidifying its role as a pioneer in genetic testing solutions specifically tailored for reproductive health. Natera has established a significant footprint in the global market with its innovative approach to genetic testing services.
 
The company is known for its comprehensive suite of reproductive health solutions that include market for Aneuploidy (PGT-A) and market for Monogenic Disorders (PGT-M). With a strong emphasis on leveraging advanced technology and data analytics, Natera has positioned itself as a leader in genetic testing, ensuring higher accuracy and precision in its offerings. The company continuously invests in research and development to enhance its product portfolio and expand its market presence.
 
Recent mergers and acquisitions have also bolstered Natera's capabilities, allowing it to integrate complementary technologies and services, which further strengthens its competitive edge within the global landscape. As Natera continues to innovate and broaden its reach, it remains closely aligned with the evolving needs of clinicians and patients alike, driving forward the adoption of genetic testing in reproductive health practices.

Key Companies in the Preimplantation Genetic Testing Market include

Industry Developments

The Global Preimplantation Genetic Testing Market has recently witnessed significant developments, notably with companies like BioMarin Pharmaceutical and Natera enhancing their offerings through innovative testing solutions. Illumina has expanded its market presence by launching advanced sequencing technologies aimed at improving genetic testing accuracy. In September 2023, Roche announced a partnership with Genea Limited to enhance integrated solutions for reproductive health, indicating a strategic push towards comprehensive genetic testing. Notably, Thermo Fisher Scientific and Quest Diagnostics have reported considerable growth in their testing services, reflecting a surge in demand for genetic testing in fertility treatments.

In the merger and acquisition space, Charles River Laboratories acquired a genetic testing firm in August 2023, reinforcing its position in this niche market. Laboratory Corporation of America has also been involved in expanding its genetic testing capabilities, emphasizing the growing importance of precision medicine. Over the past two to three years, the market has experienced substantial valuation growth, driven by technological advancements and an increasing awareness of genetic disorders among prospective parents. The focus on personalized medicine and genetic insights has led to a robust forecast for the global market.

Future Outlook

Preimplantation Genetic Testing Market Future Outlook

The Preimplantation Genetic Testing Market size is projected to reach USD 4.492 Billion by 2035, growing at a CAGR of 7.11, driven by technological advancements, increasing infertility rates, and rising awareness of genetic disorders.

New opportunities lie in:

  • Development of AI-driven genetic analysis software for enhanced accuracy. Expansion of telehealth services for remote genetic counseling. Partnerships with fertility clinics to offer bundled testing services.

By 2035, the Preimplantation Genetic Testing Market share is expected to be robust, driven by innovation and strategic partnerships.

Market Segmentation

Preimplantation Genetic Testing Market End Use Outlook

  • Fertility Clinics
  • Research Laboratories
  • Hospitals

Preimplantation Genetic Testing Market Technique Outlook

  • Polymerase Chain Reaction
  • Next Generation Sequencing
  • Fluorescence In Situ Hybridization
  • Single Nucleotide Polymorphism

Preimplantation Genetic Testing Market Application Outlook

  • Diagnostic Testing
  • Carrier Screening
  • Embryo Selection

Preimplantation Genetic Testing Market Client Type Outlook

  • Individuals
  • Healthcare Providers
  • Healthcare Institutions

Report Scope

MARKET SIZE 2024 2.11(USD Billion)
MARKET SIZE 2025 2.26(USD Billion)
MARKET SIZE 2035 4.492(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.11% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Illumina (US), Thermo Fisher Scientific (US), Fulgent Genetics (US), Natera (US), CooperSurgical (US), Preimplantation Genetic Diagnosis (UK), Genea (AU), Reproductive Health Technologies (US), Mayo Clinic (US)
Segments Covered Applications, Technique, End Use, Client Type, Regional
Key Market Opportunities Advancements in gene editing technologies enhance accuracy and accessibility in the Preimplantation Genetic Testing Market.
Key Market Dynamics Rising demand for personalized medicine drives advancements in Preimplantation Genetic Testing technologies and regulatory frameworks.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the market?

The market valuation reached 2.11 USD Billion in 2024.

What is the projected market size for the market by 2035?

The market is expected to grow to 4.492 USD Billion by 2035.

What is the expected CAGR for the market during the forecast period?

The market is anticipated to experience a CAGR of 7.11% from 2025 to 2035.

Which application segments are driving growth in the Preimplantation Genetic Testing Market?

Diagnostic Testing, Carrier Screening, and Embryo Selection are key application segments, with valuations of 1.78, 1.35, and 1.37 USD Billion respectively by 2035.

What techniques are primarily utilized in Preimplantation Genetic Testing?

The market employs techniques such as Polymerase Chain Reaction, Next Generation Sequencing, Fluorescence In Situ Hybridization, and Single Nucleotide Polymorphism.

How do the end-use segments contribute to the Preimplantation Genetic Testing Market?

Fertility Clinics, Research Laboratories, and Hospitals are projected to generate revenues of 1.78, 1.36, and 1.35 USD Billion respectively by 2035.

Who are the key players in the Preimplantation Genetic Testing Market?

Prominent players include Illumina, Thermo Fisher Scientific, Fulgent Genetics, and Natera, among others.

What client types are involved in the Preimplantation Genetic Testing Market?

The market serves Individuals, Healthcare Providers, and Healthcare Institutions, with projected revenues of 1.78, 1.45, and 1.25 USD Billion respectively by 2035.

What factors are influencing the growth of the Preimplantation Genetic Testing Market?

Advancements in genetic testing technologies and increasing awareness among healthcare providers and individuals are likely driving market growth.

How does the Preimplantation Genetic Testing Market compare to other genetic testing markets?

While specific comparisons are complex, the Preimplantation Genetic Testing Market's growth trajectory appears robust, particularly with its projected CAGR of 7.11% from 2025 to 2035.

Author
Author
Author Profile
Nidhi Mandole LinkedIn
Senior Research Analyst
She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

Research Approach

 

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed reproductive medicine journals, genetic testing publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health, European Medicines Agency (EMA), Centers for Disease Control and Prevention (CDC) Assisted Reproductive Technology Surveillance, American Society for Reproductive Medicine (ASRM), European Society of Human Reproduction and Embryology (ESHRE), Society for Assisted Reproductive Technology (SART), College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA) database, National Institutes of Health (NIH) National Human Genome Research Institute, National Center for Biotechnology Information (NCBI/PubMed), World Health Organization (WHO) Reproductive Health Database, Human Fertilisation and Embryology Authority (HFEA), EU Eurostat Health Database, and national health ministry reports from key markets. These sources were used to collect IVF procedure statistics, PGT regulatory approval data, clinical efficacy studies, chromosomal abnormality screening trends, and market landscape analysis for next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, and single nucleotide polymorphism technologies.

 

Primary Research

To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research phase. CEOs, VPs of Product Development, heads of regulatory affairs, and commercial directors from genetic testing platforms, IVF device manufacturers, chains of fertility clinics, and diagnostic laboratory service providers were examples of supply-side sources. Board-certified reproductive endocrinologists, embryologists, genetic counselors, laboratory directors, medical directors of fertility clinics, and procurement leaders from hospital reproductive medicine departments and research labs were examples of demand-side sources. Primary research confirmed product pipeline timelines for NGS and PCR innovations, validated market segmentation across diagnostic testing, carrier screening, and embryo selection applications, and collected data on reimbursement dynamics, pricing strategies for PGT cycles, and clinical adoption patterns.

Primary Respondent Breakdown:

By Designation: C-level Primaries (30%), Director Level (35%), Others (35%)

By Region: North America (40%), Europe (28%), Asia-Pacific (25%), Rest of World (7%)

 

Market Size Estimation

Global market valuation was derived through revenue mapping and PGT procedure volume analysis. The methodology included:

Identification of 45+ key manufacturers across genetic testing platforms, IVF device manufacturers, and fertility clinic networks in North America, Europe, Asia-Pacific, and Latin America

Product mapping across next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, and single nucleotide polymorphism technologies

Analysis of reported and modeled annual revenues specific to preimplantation genetic testing portfolios

Coverage of manufacturers representing 70-75% of global market share in 2024

Extrapolation using bottom-up (PGT procedure volume × ASP by country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations for fertility clinics, research laboratories, and hospital end-use segments

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035